AXGN - AxoGen Inc. (AXGN) Q4 2023 Earnings Call Transcript
2024-03-05 11:03:13 ET
AxoGen, Inc. (AXGN)
Q4 2023 Earnings Call Transcript
March 05, 2024, 08:00 AM ET
Company Participants
Harold Tamayo - VP, Finance and IR
Karen Zaderej - Chairman, CEO and President
Nir Naor - CFO
Conference Call Participants
Chris Pasquale - Nephron
Mike Sarcone - Jefferies
Mike Kratky - Leerink Partners
Caitlin Cronin - Canaccord Genuity
Dave Turkaly - Citizens JMP
Ross Osborn - Cantor Fitzgerald
Presentation
Operator
Hello, and welcome to the AxoGen, Inc. 2023 Fourth Quarter and Full Year Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Harold Tamayo, Vice President, Finance and Investor Relations. Harold, you may now begin.
Harold Tamayo
Thank you, Kevin, and good morning, everyone. Joining me on today's call is Karen Zaderej, AxoGen's Chairman, Chief Executive Officer and President, and Nir Naor, Chief Financial Officer. Karen will discuss the quarter and full year 2023, and Nir will provide an analysis of our financial performance, guidance and discuss our outlook for the year, followed by a question-and-answer session. Today's call is being broadcast live via webcast, which is available on the Investors section of the AxoGen website. Following the end of the live call, a replay will be available in the Investors section of the company's website at www.axogeninc.com.
Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements, including our expectations regarding our ability to expand our footprint, expand core accounts, anticipate growth for revenue categories, penetration of core accounts, marketing opportunities with nerve applications associated with emerging trauma, breast, OMF and surgical treatment of pain and new products, our expectations regarding the timing of our launch for Avive+, our statement regarding the timing of the complete biologics license application submission for Avance Nerve Graft, as well as statements of the timing of the approved BLA. Our expectation is that, assuming approval of the the BLA, Avance Nerve Graft will be designated as the reference product and expected market exclusivity of such designation....
AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript